News $40bn Teva generic deal awaits antitrust approval Acquisition of Allergan's generics business ready.
News Impax buys Teva and Allergan generics for $586 million Teva must sell some assets before buying Allergan's generics business.
News Teva walks away from Mesoblast's heart failure drug Mesoblast to continue developing stem cell based therapy.
Articles Teva: looking for innovation and growth in ‘space between’ b... Teva is looking to evolve its business through new R&D programmes and development of 'New Therapeutic Entities' from off-patent drugs.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
